2. Academic Validation
  3. Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma

  • Cancer Cell. 2020 May 11;37(5):674-689.e12. doi: 10.1016/j.ccell.2020.03.016.
Elie Dheilly 1,  Elena Battistello 2,  Natalya Katanayeva 1,  Stephanie Sungalee 1,  Justine Michaux 3,  Gerben Duns 4,  Sarah Wehrle 5,  Jessica Sordet-Dessimoz 6,  Marco Mina 7,  Julien Racle 8,  Pedro Farinha 4,  George Coukos 3,  David Gfeller 8,  Anja Mottok 9,  Robert Kridel 10,  Bruno E Correia 11,  Christian Steidl 4,  Michal Bassani-Sternberg 3,  Giovanni Ciriello 7,  Vincent Zoete 12,  Elisa Oricchio 13
Affiliations

Affiliations

  • 1 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland.
  • 2 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Department of Computational Biology, University of Lausanne, 1015 Lausanne, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.
  • 3 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
  • 4 Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada.
  • 5 Institute of Bioengineering, EPFL, 1015 Lausanne, Switzerland.
  • 6 Histology Core Facility, EPFL, 1015 Lausanne, Switzerland.
  • 7 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Department of Computational Biology, University of Lausanne, 1015 Lausanne, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland.
  • 8 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Department of Oncology, University Hospital of Lausanne, Lausanne, Switzerland.
  • 9 Institute of Human Genetics, Ulm University and Ulm University Medical Center, Germany.
  • 10 Princess Margaret Cancer Center, Toronto, Canada.
  • 11 Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Institute of Bioengineering, EPFL, 1015 Lausanne, Switzerland.
  • 12 Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne 1015, Switzerland; Ludwig Institute for Cancer Research and Department of Oncology, University of Lausanne, Lausanne, Switzerland; Molecular Modeling Group, SIB, Lausanne, Switzerland.
  • 13 Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne, 1015 Switzerland; Swiss Cancer Center Leman (SCCL), Lausanne, 1015 Switzerland. Electronic address: [email protected].
PMID: 32330455 DOI: 10.1016/j.ccell.2020.03.016
Abstract

Genomic alterations in Cancer cells can influence the immune system to favor tumor growth. In non-Hodgkin lymphoma, physiological interactions between B cells and the germinal center microenvironment are coopted to sustain Cancer cell proliferation. We found that follicular lymphoma patients harbor a recurrent hotspot mutation targeting tyrosine 132 (Y132D) in Cathepsin S (CTSS) that enhances protein activity. CTSS regulates antigen processing and CD4+ and CD8+ T cell-mediated immune responses. Loss of CTSS activity reduces lymphoma growth by limiting communication with CD4+ T follicular helper cells while inducing antigen diversification and activation of CD8+ T cells. Overall, our results suggest that CTSS inhibition has non-redundant therapeutic potential to enhance anti-tumor immune responses in indolent and aggressive lymphomas.

Keywords

T cells; antigen presentation; cysteine proteases; germinal centers; immunotherapy; lymphoma.

Figures
Products